New Multi-faceted support service

New Multi-faceted support service is launched for newly diagnosed patients with Ulcerative Colitis taking Mesalazine

29 March 2007, Today, a new patient support service is being launched at the British Society of Gastroenterology (BSG) annual meeting.  The service is for newly diagnosed patients with ulcerative colitis (UC), who have been prescribed mesalazine treatment. 

The new service called “Everyday-Living” is designed to supplement the service patients currently receive from their healthcare professionals, enhance the patient experience and ultimately to improve their well-being. It aims to help patients better understand their condition and provide education to them on the long-term management of UC.

“A patient’s attitude towards UC and their treatment is formed in the first few months following diagnosis.  If a patient receives enough support during this critical time, they generally understand what it means to have a chronic condition and, therefore, appreciate the need to take their medicine every day.  If a patient get this right, the chances are they will have fewer flare-ups and reduce their risk of needing surgery,” said Dr Andrew Robinson, Consultant Gastroenterologist, Hope Hospital, Manchester.

As with most chronic conditions, compliance is a major problem in UC.  Research suggests that up to 60 per cent of UC patients do not take their medication as prescribed1 putting them at increased risk of relapse and surgery.2

“Everyday-Living” is tailored to your newly diagnosed UC patients because it has many different but complementary components including:
· A telephone support service
· Intermittent letters and disease awareness leaflets
· Quarterly lifestyle magazines
· Dedicated patient website

Allison Nightingale, IBD Nurse Specialist, Addenbrooke’s NHS Foundation Trust, Cambridge said, “This will be a very valuable resource, particularly for those patients that do not have access to an inflammatory bowel disease (IBD) nurse specialist.”

After recommendation from their gastroenterologist or IBD nurse newly diagnosed UC patients on mesalazine treatment can sign-up for the service by completing a registration form or calling a free phone number.

The new support service supported by Procter & Gamble Pharmaceuticals will be monitored and its impact on patient behaviour and well-being evaluated on an ongoing basis.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in